Untreated Adult Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.
Verified date | June 2022 |
Source | Case Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Midostaurin may help azacitidine kill more cancer cells by making the cancer cells more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and best dose of midostaurin when given together with azacitidine and to see how well it works in treating elderly patients with acute myelogenous leukemia.
Status | Completed |
Enrollment | 34 |
Est. completion date | May 5, 2017 |
Est. primary completion date | September 8, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria - Patients must have histologic proof of active AML at time of enrollment - Phase I and II portion: Subjects of any age with untreated AML, if not candidates for standard induction chemotherapy or with poor risk AML (i.e. preceding MDS, myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse cytogenetics or complex karyotype), or any subjects > 70 years of age with untreated AML. Acute promyelocytic leukemia (FAB M3) is excluded - Please note: prior intensive induction therapy for acute leukemia is allowed only in the phase I portion of this study • PHASE I PORTION ONLY: Patients of any age who have received no more than one prior attempt at induction chemotherapy (and may have received treatment consolidation), must have recovered from acute toxicities of therapy and be >= 4 weeks from last dose of cytotoxic treatment; patients who have received prior autologous or allogeneic stem cell transplantation are not eligible; patients may have received 1 or 2 cycles of cytarabine-based therapy as attempted induction. - Phase II portion: Patients must have not received any prior intensive induction therapy for AML. - Intensive induction includes standard induction chemotherapy such as 7 & 3, high dose cytarabine, mitoxantrone-etoposide, low-dose subcutaneous cytarabine. - Allowed "non-intensive" prior treatments for pre-existing hematologic conditions (i.e., MDS, chronic myelomonocytic leukemia [CMML]) will include: hydroxyurea, thalidomide, hematopoietic growth factors, Zarnestra, Lenalidomide, arsenic, Imatinib, and corticosteroids, suberoylanilide hydroxamic acid [SAHA] inhibitors; hydroxyurea is allowed up to 24 hours before initiating treatment and to control blood counts during the first cycle of chemotherapy after azacitidine has completed; a minimum of 4 weeks must have elapsed since the administration of thalidomide, Zarnestra, Revlimid, arsenic, SAHA inhibitors, or any investigational medication; a minimum of five days must have elapsed since the administration of growth factors - Prior cytotoxic chemotherapy for another condition treated with curative intent is allowed provided at least 18 months has elapsed between last treatment and enrollment on protocol - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 times the upper limits of normal - Serum bilirubin =< 1.5x upper limit of normal - Creatinine =< 1.5x upper limit of normal - No exclusion for blood counts; however, at the time of treatment initiation, white blood cell (WBC) should be < 30,000/uL (can be controlled with hydroxyurea) - Life expectancy without treatment of at least 12 weeks - Patients with and without FLT3 mutations will be eligible to participate - Patients must have the ability and willingness to sign a written informed consent document Exclusion Criteria - Acute promyelocytic leukemia (FAB M3) - Prior autologous or allogeneic stem cell transplant - Prior azacitidine, decitabine, or midostaurin - Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin; patients with gastric bypass surgery are excluded - Patients with any other known active cancer (except carcinoma in-situ), concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, pulmonary, chronic renal disease, active uncontrolled infection) - Cardiovascular Criteria will exclude a patient from participation in the study will include: - Screening electrocardiogram (ECG) with a QTc > 450 msec; - Patients with congenital long QT syndrome; - History or presence of sustained ventricular tachycardia; - Any history of ventricular fibrillation or torsades de pointes; - Bradycardia defined as heart rate (HR) < 50 bpm; - Right bundle branch block + left anterior hemiblock (bifascicular block); - Patients with myocardial infarction or unstable angina < 6 months prior to starting study drug; - Congestive heart failure (CHF) New York (NY) Heart Association class III or IV; - Patients with an ejection fraction =< 45% assessed by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) scan within 14 days of day 1 - Poorly controlled hypertension - Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin - Active or suspicion of central nervous system (CNS) leukemia - Patients with human immunodeficiency virus (HIV) disease or active viral hepatitis - Patients with hepatitis B - Patients with an abnormal chest X-ray and/or any pulmonary infiltrate including those suspected to be of infectious origin; in particular, patients with resolution of clinical symptoms of pulmonary infection but with residual pulmonary infiltrates on chest x-ray are not eligible until pulmonary infiltrates have completely resolved - Pregnant or lactating women - Prohibited medications: PKC412 and its two major metabolites may have a potential of drug-drug interactions with P-gp substrates and CYP3A4 inhibitors, and inducers. An increased anticoagulant effect has been noted in patients treated with warfarin and midostaurin. - Patients who have received any investigational agent within 30 days prior to day 1 - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months of midostaurin medication. Highly effective contraception methods include: - Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception - Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment - Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject. - Combination of any two of the following (a+b or a+c, or b+c): 1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment Sexually active males unless they use a condom during intercourse while taking drug and for 5 months after stopping midostaurin medication. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio |
United States | West Virginia University | Morgantown | West Virginia |
Lead Sponsor | Collaborator |
---|---|
Brenda Cooper, MD | National Cancer Institute (NCI) |
United States,
Tomlinson BK, Gallogly MM, Kane DM, Metheny L, Lazarus HM, William BM, Craig MD, Levis MJ, Cooper BW. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):226-233.e1. doi: 10.1016/j.clml.2019.10.018. Epub 2019 Nov 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pharmacokinetic Profile of Midostaurin Given With Azacitidine (Phase I) | Change in Midostaurin trough levels and active metabolite levels between cycles one and two | after 2 cycles | |
Other | Changes of Phosphorylation Status of FLT3 in Blood and Bone Marrow Samples (Phase I/II) | Baseline to 4 cycles (16 weeks) | ||
Primary | Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I) | Patients received azacitidine 75 mg/m intravenous over 30 minutes daily for 7 consecutive days followed by escalating doses of oral midostaurin (25 mg bid, 50 mg bid, and 75 mg bid) days 8-21. Determination of the maximum tolerated dose (MTD) was based on dose-limiting toxicities (DLT) observed during the first cycle of treatment | Day 28 | |
Primary | Number of Participants With Hematologic Improvement (Phase I) | Number of participants with HI. Hematologic improvement (HI): must last at least 2 months in the absence of ongoing cytotoxic therapy and will be another endpoint of interest (although it will not be considered in the final statistical analysis) and will be defined according to IWG criteria . | After 2 cycles of therapy | |
Primary | Overall Response Rate (Phase II) | Number of participants with CR, CRi, PR and Hematologic improvement (HI). Response will be assessed using the standard morphologic criteria for acute leukemia as follows: Complete remission (CR): ANC = 1000/ uL and platelets of > 100,000/ uL without circulating blasts and bone marrow with < 5% blasts and no Auer rods; Morphologic complete remission with incomplete blood recovery (CRi): Patients fulfills all of the criteria for remission except for residual neutropenia (ANC < 1000/ uL) or thrombocytopenia (platelet count < 100,000/uL). Partial remission (PR): This designation requires at least a 50% decrease in the bone marrow blasts to 5-25%. | after 4 months of treatment | |
Primary | Toxicity Profile (Phase II) | Number of patients experiencing at least one instance of specific treatment emergent adverse events | during treatment up to 10 cycles | |
Secondary | Duration of Response | Time to progression after confirmed response | Up to 3 years | |
Secondary | Overall Survival (Phase II) | Median time of overall survival of participants from initiation of midostaurin-azacitidine | Up to 3 years | |
Secondary | Correlate Treatment Response With FLT3 Mutational Status in a Descriptive Fashion.(Phase I) | Number of participants with FLT3 mutation that had a response to treatment | Baseline to 4 cycles (16 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01564277 -
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT01690065 -
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
|
Phase 2 | |
Completed |
NCT01141725 -
Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT00742625 -
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Completed |
NCT00093418 -
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00096122 -
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Terminated |
NCT00049582 -
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
Phase 1 | |
Completed |
NCT01798901 -
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
|
Phase 1 | |
Terminated |
NCT01876953 -
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT02583893 -
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT01555268 -
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Terminated |
NCT01907815 -
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT01519596 -
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
|
N/A | |
Completed |
NCT00407966 -
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00095797 -
XK469R in Treating Patients With Refractory Hematologic Cancer
|
Phase 1 | |
Terminated |
NCT00096148 -
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00101296 -
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 |